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Regulation of TNF-a by 1a,25-dihydroxyvitamin D3 in human lite of vitamin D3, is not limited to mineral and skeletal
macrophages from CAPD patients. homeostasis [1, 2]. In recent years, there has been in-
Background. We have previously reported that 1a,25-dihy- creasing evidence pointing to the role of 1a,25(OH)2D3droxyvitamin D3 [1a,25(OH)2D3] accumulates in the dialysis
and its analogues in the regulation of cell growth. Thisfluid of uremic patients treated by continuous ambulatory peri-
includes the antiproliferative effect on cancer cells andtoneal dialysis (CAPD). It has been reported that this metabo-
lite regulates the production of cytokines by monocytes/macro- the induction of differentiation of leukemia cells into
phages. Since tumor necrosis factor-a (TNF-a) initiates an normal monocytes/macrophages [3]. Additionally, con-
inflammatory cascade during peritonitis, the aim of the present vincing evidence has been gathered indicating thatstudy was to investigate the effect of 1a,25(OH)2D3 on the pro-
1a,25(OH)2D3 is an important immune response regulatorduction of TNF-a by human peritoneal macrophages (HPMs).
Methods. HPMs were obtained from patients on CAPD. Cells at inflammatory sites. Such a property of 1a,25(OH)2D3
were incubated with various concentrations of 1a,25(OH)2D3, may find expression in the special microenvironment
1a,24(S) dihydroxyvitamin D2 [1a,24(S)(OH)2D2] or 25-hydrox- of the peritoneal cavity characteristic of the continuous
yvitamin D3 (25-OH-D3) for 16 hours. This was followed by ambulatory peritoneal dialysis (CAPD) technique. Thus,lipopolysaccharide (LPS; 1 mg/mL) incubation for 2.5 to 6 hours.
we have previously demonstrated that 1a,25(OH)2D3 ac-TNF-a protein production was determined by enzyme-linked
immunosorbent assay. TNF-a mRNA was assayed by the re- cumulates in the peritoneal fluid of CAPD patients
verse transcriptase-polymerase chain reaction procedure, using through two mechanisms: (1) 1a,25(OH)2D3 and its sub-
internal synthetic mRNA standards for quantitative results. strate 25(OH)D3, combined with their binding proteinResults. Incubation of HPMs with 1a,25(OH)2D3 prior to
leak from the blood stream through the peritoneal capil-stimulation with LPS dose dependently inhibited the expres-
laries into the dialysate, and (2) 1a,25(OH)2D3 synthe-sion of TNF-a on both mRNA and protein levels. Similar
results were obtained with the less calcemic vitamin D2 ana- sized by the peritoneal macrophages, where the substrate
logue 1a,24(S)(OH)2D2. Incubation of HPMs with 25-OH-D3 is converted into the active metabolite of vitamin D [4–6].
also revealed a down-regulation of TNF-a expression. Since
We have demonstrated that 1a,25(OH)2D3 signifi-this down-regulatory effect was blocked by ketoconazole, it is
cantly increases superoxide generation and bactericidallikely that this effect was caused by the conversion of 25-OH-D3
into 1a,25(OH)2D3 by HPMs. activity of peritoneal macrophages [6]. This is particu-
Conclusions. 1a,25(OH)2D3 has a potent inhibitory effect larly relevant in view of the importance of peritoneal
on the production of TNF-a by LPS-activated HPMs. We hy- macrophages in the host defense mechanism of the peri-pothesize that 1a,25(OH)2D3 may constitute a regulatory mech-
toneal cavity in CAPD patients. It is noteworthy, how-anism that, by controlling the intensity of the inflammatory
ever, that in such patients, the capacity of macrophagesresponse of the peritoneum, will moderate tissue damage dur-
ing peritonitis. to phagocyte microorganisms is severely limited because
of the diluting effect of the infused dialysis solution on
the peritoneal macrophage population. Consequently,
It is well established that the physiological role of 1a,25- within this context, the contribution of the peritoneal
dihydroxyvitamin D3 [1a,25(OH)2D3], the active metabo- macrophages in combating bacterial invasion relies
mainly on their ability to secrete inflammatory cytokine
effectors, such as interleukin-1 (IL-1) and tumor necrosisKey words: cytokines, inflammation, immune system, CAPD, peritoni-
tis, cell growth, vitamin D. factor-a (TNF-a).
It is interesting to note that in recent years, conflictingReceived for publication October 27, 1999
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in laboratory techniques and conditions, cell type, etc. dium and replacing it with fresh medium. The adherent
cells were released by addition of phosphate-buffered[10–14]. For example, using the human myelomonocytic
cell line U-937, Fagan et al [12] and Prehn et al [10] saline and rolling glass sticks in the flask. Following isola-
tion of macrophages, the cells were counted by a hemocy-showed that 1,25a(OH)2D3 causes a dose-dependent in-
crease in TNF-a and IL-1b production in lipopolysaccha- tometer and adjusted to 1 3 106 cells/mL. More than
99% HPMs were viable as determined by trypan blueride (LPS)-stimulated cells. On the other hand, Riancho
et al recently demonstrated a down-regulation of TNF-a exclusion.
expression [15] and Panichi et al showed a down-regula-
Incubation of HPMstion of IL-1b and TNF-a expression in LPS-stimulated
human peripheral blood monocytes [16]. To date, no Primary cultures of HPMs (1 3 106 cells/tube) were
seeded in plastic tissue culture tubes (12.4 3 75 mm;data are available regarding the role of 1a,25(OH)2D3 in
cytokine production by human peritoneal macrophages Falcon Plastics, Rohrchen, Greiner, Frickenhausen, Ger-
many) by placing 1 mL cell suspension in 10% FCS(HPMs). The present study was designed to investigate
the regulatory effect of 1a,25(OH)2D3 on the generation containing RPMI-1640 medium into each tube and incu-
bated as monolayers overnight. Treatments and activa-of TNF-a by peritoneal macrophages of CAPD patients.
We believe such an investigation could be of particular tion were performed in triplicate as follows. Overnight
supernatants were removed and the cells were incubatedclinical value since in the peritoneal environment, there
is a simultaneous up-regulation of TNF-a production and in RPMI medium containing 2% FCS with various con-
centrations of 1a,25(OH)2D3 (10210 to 1027 mol/L) for1a,25(OH)2D3 synthesis in response to bacterial invasion.
16 hours. The cells were then exposed to 1 mg/mL of
lipopolysaccharide (LPS; Escherichia coli 055:B5 LPS;
METHODS
Sigma, St. Louis, MO, USA) for six hours for protein
Materials expression or for 2.5 hours for mRNA expression.
Cells were also incubated under the same conditions1a,25(OH)2D3 and 25-hydroxyvitamin D3 (25-OH-D3)
were kindly provided by Hoffman La-Roche (Basel, with various concentrations of the synthetic analogue
1a,24(S)(OH)2D2 (10210 to 1027 mol/L) or with 25-OH-D3Switzerland) and 1a,24(S)-dihydroxyvitamin D2 by Bone
Care International Co. (Madison, WI, USA). Each com- (10210 to 1026 mol/L). Following the incubation period,
tubes were placed on ice, and supernatants were collectedpound was dissolved in ethanol and stored in a concen-
trated solution at 2208C that was protected from light. and stored at 2208C for TNF-a protein determination.
Cells were subjected to mRNA extraction procedure. AVitamin D metabolites were freshly diluted in the appro-
priate culture medium before each experiment. The final viability of more than 99% of cells was determined by
Trypan blue exclusion in the HPM primary cultures.ethanol concentration did not exceed 0.1%.
Similar incubations of the mice monocyte-macrophage-
Cell preparation like cell line P388D1 with 1a,25(OH)2D3 (10210 and 1027
mol/L) were carried out using the same experimentalHuman peritoneal macrophages were obtained from
effluent dialysates of patients in end-stage renal disease protocol.
undergoing CAPD treatment. All patients were treated
TNF-a mRNA analysiswith 1a-hydroxyvitamin D3 (0.25 to 1 mg/day). This treat-
ment was discontinued two weeks before the experiment Tumor necrosis factor-a mRNA was determined by
reverse transcriptase-polymerase chain reaction (RT-took place. Isolation of macrophages from the dialysate
fluids was performed as described elsewhere [4, 17, 18] PCR) of total RNA extracted from HPMs. HPMs were
incubated as described previously in this article. At thewith a few modifications. Complete dialysate effluent vol-
ume was centrifuged at 2000 r.p.m. 3 15 minutes (Hettich, end of each experiment, the supernatants were removed,
and cells were lyzed with 0.75 mL Tri Reagent (Molecu-Rotanta/RP, Tuttlingen, Germany). Cells were washed
with Hank’s solution and centrifuged again at 1500 lar Research Center, Inc., Cincinnati, OH, USA). For
TNF-a mRNA determination, we employed the methodsr.p.m. 3 10 minutes. Then the cells were washed twice
in RPMI-1640 medium (Bet-Haemek, Israel) and resus- of Bouaboula et al [19] and Legoux et al [20], using
a quantitative RT-PCR procedure. This method usespended in RPMI-1640 medium, which contained 10% fe-
tal calf serum (FCS), 2 mmol/L l-glutamin, 100 U/mL internal standard RNA obtained from synthetic DNA
construct containing TNF-a primer sites identical to thepenicillin, 10 mg/mL streptomycin, and 12.5 U/mL nistat-
ine (Biological Industries, Bet-Haemek, Israel). Cells primer sites of native TNF-a mRNA.
were plated into a plastic flask and incubated for 90
cDNA preparationminutes at 378C in humidified atmosphere of 5% CO2
and 95% air to allow the attachment of macrophages. For cDNA generation, a synthetic RNA mixture
(0.0325 ng) and a reverse transcriptase reaction mixtureNonadherent cells were removed by discarding the me-
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were added to each RNA sample. This mixture contained compensate differences in RT and PCR efficiency, and
results were then normalized according to b-actin levels1 mL of Moloney murine leukemia virus-reverse tran-
scriptase (MMLV-RT, 200 U/mL; GIBCO BRL, Gaith- to compensate differences in mRNA between the vari-
ous samples. Results were compared with those of LPS-ersburg, MD, USA), 4 mL of 5 3 reverse transcriptase
buffer (GIBCO BRL), 0.25 mL dithiothreitol (DTT; 0.1 stimulated HPMs.
mol/L; GIBCO BRL), 0.5 mL RNase inhibitor (40 U/mL;
TNF-a protein determinationBoehringer Mannheim, Mannheim, Germany), 1 mL
oligo-d(T) 12-18 mer (40 pmol/mL; Boehringer Mann- Tumor necrosis factor-a protein levels were measured
in the supernatants of HPM cultures in triplicate by anheim), and 1 mL dNTP (2.5 nmol/mL of each nucleotide;
Boehringer Mannheim). The tubes were incubated for enzyme-linked immunosorbent assay (ELISA) for hu-
man TNF-a using a commercially available paired anti-one hour at 378C. Then the volume of each sample was
adjusted to 50 mL, and the enzyme was inactivated by bodies assay (R&D Systems, Minneapolis, MN, USA),
as per the protocol of the manufacturer. Supernatantsincubation for 10 minutes at 658C.
of the P388D1 cell line were tested for TNF-a protein
Polymerase chain reaction levels using an ELISA procedure specific for mice TNF-a
(R&D Systems).Co-amplification of the standard RNA preparations
together with native mRNA obtained from HPMs fol-
Determination of 1a,25(OH)2D3 production by HPMlowed by quantitation of PCR products were carried out.
Native TNF-a (427 bp), synthetic TNF-a (370 bp), and Human peritoneal macrophages (1 3 106 cells/tube)
in RPMI-1640 medium were incubated with 25-OH-D3b-actin (263 bp) cDNA were then amplified by PCR using
specific primers. A portion of 5 mL of reverse transcrip- (1026 mol/L) as a substrate for 16 hours with or without
the cytochrome P450 inhibitor, ketoconazole. The reac-tion product was added to 45 mL of PCR reaction mixture
containing 30 mL H2O, 2.5 mL 59-primer (20 mmol/L), tion was terminated by addition of 1 mL acetonitrile [high-
performance liquid chromatography (HPLC) grade; Bio-2.5 mL 39-primer (20 mmol/L), 2 mL dNTP (2.5 nmol/mL
of each nucleotide; Boehringer Mannheim), 5 mL of reac- lab, Jerusalem, Israel]. A tracer of 1000 CPM [3H] 1a,
25(OH)2D3 (Hamersham, Little Chalfont, Buckingham-tion buffer, and 0.2 mL Red Hot DNA polymerase
(5 U/mL; Advanced Biotechnologies, Surrey, UK). A shire, UK) was added to each sample for recovery esti-
mation. Assessment of the 1a,25(OH)2D3 produced bynegative control consisting of the reaction mixture with-
out cDNA was included in each run. PCR for b-actin was HPM was carried out following lipid extraction and
1a,25(OH)2D3 isolation by a Sep-pak separation proce-performed at 25 cycles. The PCR was done with b-actin
primers under the following conditions: 90 seconds at dure. The isolated 1a,25(OH)2D3 fraction was subjected
to a vitamin D receptor (VDR) radioligand competitive948C, then 10 cycles of 45 seconds each at 948C, 1.5
minutes at 608C, and 1 minute at 728C. The last 15 cycles binding assay [21] using calf thymus VDR [22]. The re-
sults (pg/mL) were adjusted with respect to recoverywere run under the same conditions, but the 728C step
was prolonged by five seconds in each cycle. PCR with values.
native and synthetic TNF-a primers was performed using
Statistical analysisthe same protocol. Every experiment was amplified with
at least two different cycle numbers to assure that ampli- Results are presented as mean 6 SEM. Student t test
was used to compare TNF-a levels between treatments.fication was in the exponential phase of PCR. We found
that 30 cycles for TNF-a and 25 cycles for b-actin were P values below 0.05 were considered significant.
in the exponential phase of amplification in our experi-
ments, thus permitting comparison of mRNA levels in
RESULTS
different samples. Under these conditions, we also found
Effect of 1a,25(OH)2D3 on TNF-a mRNA levelsa linear dose–response of the PCR products to increasing
doses of original cDNA. Eight microliters of each sample Reverse transcriptase-PCR of total RNA from HPMs
yielded a band of mRNA for TNF-a at the expectedcontaining amplified cDNA of the two kinds of TNF-a,
together with 8 mL of the corresponding sample containing size of 427 bp (Fig. 1A). The RT-PCR products of the
synthetic RNA of TNF-a yielded cDNA at the expectedamplified cDNA of b-actin, were loaded on an agarose
gel (2%) containing ethidium bromide (0.5 mg/mL). A size of 370 bp. The synthetic RNA of TNF-a accompa-
nied each treatment in order to normalize the differencesmixture of DNA size marker was run on the same gel
(123 bp ladder; GIBCO BRL). PCR products were quan- in loading amounts. As shown in Figure 1A and in its
densitometric evaluation expressed in Figure 1B, TNF-atitated by a video densitometry of agarose gel with the
UV GDS 5000 system (UVP Inc., San Gabriel, CA, mRNA was detected in untreated primary HPM cultures
only at minimal levels. However, TNF-a expression wasUSA). The TNF-a results were calculated for each treat-
ment by the ratios of native TNF-a/synthetic TNF-a to found to be inducible by LPS. It is clearly shown in this
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Fig. 1. Dose response of increased concentrations of 1a,25(OH)2D3
on tumor necrosis factor-a (TNF-a) mRNA production by stimulated
human peritoneal macrophages (HPM). HPM (1 3 106 cells/tube) were
incubated for 16 hours with increased concentrations of 1a,25(OH)2D3
(10210 to 1027 mol/L) followed by an additional 2.5 hours of incubation
with lipopolysaccharide (LPS; 1 mg/mL). RT-PCR was performed on
total HPM RNA and on synthetic RNA (RNA standards for TNF-a)
using specific primers for TNF-a PCR products (at 30 cycles) were
separated on 2% agarose gel containing ethidium bromide (A). Quanti-
tative evaluations of the PCR products were performed by video densi-
tometry, and the ratios between native and standard TNF-a bands were
calculated. The results are expressed as percentage (mean 6 SE) of
TNF-a mRNA levels obtained by LPS induced HPM (B). The results
represent three sets of experiments performed in triplicate on HPM
prepared from different patients. ***P , 0.001; **P , 0.01; *P , 0.05.
study that incubation of HPMs (1 3 106 cells/tube) for
2.5 hours with LPS at a concentration of 1 mg/mL induced
a very significant increase in TNF-a mRNA levels. On
the other hand, preincubation for 16 hours with increased
concentrations of 1a,25(OH)2D3 (10210 to 1027 mol/L) Fig. 2. Dose response of increased concentrations of 1a,25(OH)2D3 on
before the addition of LPS, induced a dose-dependent TNF-a protein secretion from stimulated HPM. HPM (1 3 106 cells/
tube) were incubated for 16 hours with increased concentrations (10210 todecrement in TNF-a mRNA. These effects were found
1027 mol/L) of 1a,25(OH)2D3 (A), 1a,24(OH)2D2 (B), or 25-OH-D3to be at statistically significant levels. As shown in Figure (C) in concentrations of (10210 to 1026 mol/L). This was followed by
1B, a 20% decrease in TNF-a mRNA levels was ob- additional six hours of incubation with LPS (1 mg/mL). Supernatants
were collected and subsequently assayed for TNF-a protein levels byserved in the presence of 1029 mol/L 1a,25(OH)2D3 (P ,
ELISA. The results are expressed as percentage (mean 6 SE) of TNF-a0.05) and a further decrease of 40% in TNF-a mRNA ex- protein levels obtained by LPS-induced HPM. The results represent
pression was obtained by incubating HPM with 1027 mol/L three experiments performed in triplicate on cells obtained from differ-
ent patients. ***P , 0.001; **P , 0.01.1a,25(OH)2D3 (P , 0.01).
Effect of vitamin D metabolites and analogue on
TNF-a protein levels 2). TNF-a production was down-regulated significantly
Tumor necrosis factor-a expression on the protein lev- (P , 0.01) even in the presence of physiological concen-
els also was examined in HPM media using a specific trations of 1a,25(OH)2D3 (10210 mol/L) and reached a
ELISA. Preincubation of HPM for 16 hours with increas- maximal effect at 1028 mol/L (Fig. 2A). Similar incuba-
ing concentrations of vitamin D metabolites [1a,25 tion of the P388D1 monocyte-macrophage-like mice cell
(OH)2D2, 25-OH-D3] or of the vitamin D analogue [1a, line with 1a,25(OH)2D3 (10210 mol/L) revealed an inhibi-
24(S)(OH)2D2], followed by activation with LPS (1 tory effect of 22% in TNF-a protein expression reaching
mg/mL) for an additional six hours, induced a dose-re- 61.1% when higher concentrations (1027 mol/L) of
1a,25(OH)2D3 were added (detailed results not shown).lated decrement in TNF-a protein concentrations (Fig.
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Fig. 4. Effect of the 25-OH-D3-1a-hydroxylase inhibitor (ketocona-
zole) on TNF-a protein secretion by HPM. HPMs (1 3 106 cells/tube)
were incubated for 16 hours in the presence of 25-OH-D3 (1026 mol/L)
with or without ketoconazole (20 mmol/L). This was followed by addi-
tional six hours of incubation with LPS (1 mg/mL). Supernatants were
Fig. 3. Synthesis of 1a,25(OH)2D3 by HPM. HPM (1 3 106 cells/tube) collected and subsequently assayed for TNF-a protein levels by ELISA.
were incubated for 16 hours with 25-OH-D3 (1026 mol/L) with or without The results are expressed as percentage (mean 6 SE) of TNF-a protein
ketoconazole. The reaction was stopped by addition of acetonitrile. levels obtained by LPS-induced HPM. The results represent three ex-
Following extraction and chromatographic procedure, 1a,25(OH)2D3 periments performed in triplicate on cells obtained from different pa-
concentrations were determined by a specific receptor binding assay. tients. ***P , 0.001; **P , 0.01.
The results (mean 6 SE) represent three experiments performed in tripli-
cate on cells obtained from different patients. ***P , 0.001.
The results in Figure 2B summarize the effect of the
synthetic vitamin D analogue 1a,24(S)-(OH)2D2 on
TNF-a production. The effect of 1a,24(S)-(OH)2D2 on
TNF-a expression was found to be dose dependent simi-
larly to the effect of 1a,25(OH)2D3. A similar trend was
observed also by incubating HPMs with 25-OH-D3 (Fig.
2C). However, this effect of 25-OH-D3 was found to be
moderate, and higher concentrations of 25-OH-D3 were
required in order to exhibit the same down-regulation
effect on TNF-a production. This down-regulatory effect
caused by these vitamin D metabolites is specific for Fig. 5. Effect of 1a,25(OH)2D3 on TNF-a protein production by LPS-
stimulated HPM as compared with that of dexamethasone. HPMs (1 3TNF-a. No change in IL-1b protein levels could be de-
106 cells/tube) were incubated for 16 hours with 1a,25(OH)2D3tected in simultaneous measurements (data not shown). (1027 mol/L) or dexamethasone (1028 mol/L) or both. This was followed
by additional six hours of incubation with LPS (1 mg/mL). Supernatants
were collected and subsequently assayed for TNF-a protein levels byConversion of 25-OH-D3 to 1a,25(OH)2D3 and its
ELISA. The results are expressed as percentage (mean 6 SE) of TNF-aeffect on TNF-a expression
protein levels obtained by LPS-induced HPM. The results represent
three experiments performed in triplicate on cells obtained from differ-Human peritoneal macrophage obtained from patients
ent patients. ***P , 0.001; **P , 0.01.on CAPD were able to produce a significant amount of
1a,25(OH)2D3 (168.5 6 2 pg/mL) when incubated with
1026 mol/L 25-OH-D3 for 16 hours (Fig. 3). The addition tion of HPM with 25-OH-D3 followed by LPS (Fig. 4,
of 20 mmol/L ketoconazole, the cytochrome P450 inhibi- lane 6) induced a decrement in TNF-a protein expression
tor, significantly reduced (P , 0.001) the synthesis of (P , 0.001), the addition of ketoconazole (Fig. 4, lane 8)
1a,25(OH)2D3 (Fig. 3), thus suggesting the presence of blunted the down-regulation caused by 25-OH-D3. Incu-
25-hydroxy-1a-hydroxylase in these macrophages. This bation of HPM with ketoconazole and various concentra-
occurrence raises the question of whether the effect of tions (10210 to 1027 mol/L) of 25-OH-D3 (data not shown)
25-OH-D3 in regulating the expression of TNF-a is a revealed a similar trend. These results suggest that 25-
direct action of the metabolite per se or whether it relies OH-D3 must be converted to 1a,25(OH)2D3 in order to
on the macrophages’ ability to convert 25-OH-D3 to express its down-regulatory effect on TNF-a generation.
1a,25(OH)2D3. To address this question, TNF-a was The anti-inflammatory effect of 1a,25(OH)2D3 (1027
measured in supernatants of HPM incubated with 25- mol/L) on HPMs, as expressed by the reduction in TNF-a
OH-D3 (1026 mol/L) with and without 20 mmol/L keto- production (Fig. 5, lane 2), was compared with that of
dexamethasone (1028 mol/L). Although dexamethasoneconazole followed by activation with LPS. While incuba-
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had a more potent inhibitory effect on LPS-induced tissue damage will depend on the fine balance between
these two proinflammatory and anti-inflammatory sys-TNF-a secretion (Fig. 5, lane 3) than 1a,25(OH)2D3, a
combination of both of these anti-inflammatory agents tems. Adhering to this hypothesis, it is reasonable to
assume that the concomitant but opposing effects ofproduced a significantly greater inhibitory effect than
dexamethasone alone (Fig. 5, lane 4, P , 0.05). 1a25(OH)2D3, as described previously in this article, may
have clinical relevance in CAPD since they moderate
the damage to the peritoneum, which would otherwise
DISCUSSION
occur because of disregulated local accumulation of pro-
In recent years, there has been increasing evidence inflammatory molecules during peritonitis This concept
showing that beyond its role in divalent ion homeostasis, is further supported by an in vitro experimental model
1a,25(OH)2D3 may also affect immune cells and thus [24] in which reactive oxygen molecules released by acti-
function as an important regulatory agent at sites of vated polymorphonuclear leukocytes caused severe dam-
inflammation [8, 23]. The present data showing a regula- age to mesothelial cells.
tory role of 1a,25(OH)2D3 on TNF-a production by The down-regulatory effect of 1a,25(OH)2D3 is not
HPMs further emphasize this contention. We found that unique to TNF-a expression. 1a,25(OH)2D3 was found
1a,25(OH)2D3 induced a marked suppressor effect on to decrease the synthesis of IL-2 and interferon-g in
TNF-a production by LPS-stimulated peritoneal macro- activated lymphocytes, and also inhibited the expression
phages. Incubation of HPM with 1a,25(OH)2D3 prior to of IL-1, IL-6, IL-12, and TNF-a in monocytes/macro-
exposure to LPS caused a significant inhibition of TNF-a phages [9, 11, 14]. In the case of IL-12, inhibition of
expression by these cells. This inhibition of TNF-a ex- the transcription factor nuclear factor-kB (NF-kB) by
pression by 1a,25(OH)2D3 was observed on both mRNA 1a,25(OH)2D3 has been suggested as the mechanism of
and protein levels and was dose-dependent. These results inhibition of this cytokine in myelomonocytic cells [14].
are strongly supported by the inhibition of TNF-a pro- Since NF-kB is also a major TNF-a transcription factor
tein expression by 1a,25(OH)2D3, observed in the pres- [25], the suppression of TNF-a by 1a,25(OH)2D3 could
ent study in a mouse monocyte-macrophage-like cell line be explained by the same mechanism.
(P388D1). We have already demonstrated that there are two
During peritonitis, upon contact with bacterial prod- sources from which 1a,25(OH)2D3 accumulates in the
ucts, peritoneal macrophages initially secrete TNF-a. By peritoneal effluent of patients on CAPD [26]. The first,
activating other peritoneal resident cells (mainly the 1a,25(OH)2D3, together with its binding protein, leaks
mesothelium), TNF-a creates a powerful proinflamma- from the blood stream through the peritoneal capillaries,
tory cascade, which promotes massive recruitment of leu- and second, this metabolite is synthesized by the perito-
kocytes into the peritoneal cavity. We have demonstrated neal macrophages where the substrate 25(OH)D3 is con-
in the past that 1a25(OH)2D3 is able to up-regulate the verted into 1a,25(OH)2D3 [4, 5]. In the present study,
host defense mechanism of the peritoneal cavity of CAPD we showed that the synthesis of 1a,25(OH)2D3 was sup-
patients through a stimulatory effect of macrophages- pressed by ketoconazole, an inhibitor of the enzyme
generated superoxide, thus reinforcing the bactericidal 1a-hydroxylase. This finding strongly supports the notion
capacity of these cells. This phenomenon may be particu- that 25-OH-D3-1a-hydroxylase mediates the conversion
larly significant during peritonitis, since we have shown of 25(OH)D3 to 1a,25(OH)2D3 by the peritoneal macro-
that under these conditions, peritoneal macrophages will phages.
up-regulate 1a25(OH)2D3 synthesis. From these findings, It is well recognized that TNF-a plays a central role
it would seem that during bacterial peritonitis, two op- in the pathogenesis of several inflammatory conditions
posing messages are relayed by 1a25(OH)2D3 to the mac- such as rheumatoid arthritis, inflammatory bowel dis-
rophages: (1) up-regulation of superoxide production eases, and LPS-induced septic shock [27–31]. Therefore,
and (2) a suppressor effect on TNF synthesis. We can the means of suppressing the biosynthesis or activity of
hypothesize that paradoxical as it may seem, these effects TNF-a may have important clinical relevance. Indeed,
of 1a25(OH)2D3 have an important role in moderating patients suffering from rheumatoid arthritis and Crohn’s
the magnitude and the extent of the inflammatory re- disease were treated on an experimental basis with TNF-a–
sponse of the peritoneum to invading microorganisms. soluble receptors or with antibodies against TNF-a in
This contradictory pattern of behavior is known to occur order to decrease their rate of inflammation [32, 33]. In
during contact of macrophages with bacteria and can be many cases, the inflammation is suppressed by dexa-
illustrated by the production of the anti-inflammatory methasone, often at the cost of side effects. Although the
molecules: interleukin-1 receptor antagonist (IL-1RA) present results may suggest the therapeutic advantage of
and soluble TNF receptor (sTNFR) concomitantly with 1a,25(OH)2D3 as an anti-inflammatory agent, practically
the synthesis of potent proinflammatory cytokines IL-1 its use is restricted because of its hypercalcemic activity
[34]. In a previous study, we showed the antiproliferativeand TNF-a. The outcome of the disease and extent of
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NF-kappaB downregulation in transcriptional repression of theactivity of the less calcemic and synthetic vitamin D2 p40 gene. J Clin Invest 101:252–262, 1998
analogue, 1a,24(S)-(OH)2D2 [35]. This activity was found 15. Riancho JA, Zarrabeitia MT, de Francisco AL, et al: Vitamin
D therapy modulates cytokine secretion in patients with renalto be equipotential to that of 1a,25(OH)2D3 [34]. In the
failure. Nephron 65:364–368, 1993present study, it was found that incubation of HPM with
16. Panichi V, Pietro SD, Andreini B, et al: Calcitriol modulates in
1a,24(S)(OH)2D2 revealed a significant down-regulation vivo and in vitro cytokine production: A role for intracellular
calcium. Kidney Int 54:1463–1469, 1998of TNF-a expression, although less potent than that ob-
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